U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H22N4O5
Molecular Weight 398.4133
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CAMOSTAT

SMILES

CN(C)C(=O)COC(=O)Cc1ccc(cc1)OC(=O)c2ccc(cc2)NC(=N)N

InChI

InChIKey=XASIMHXSUQUHLV-UHFFFAOYSA-N
InChI=1S/C20H22N4O5/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22/h3-10H,11-12H2,1-2H3,(H4,21,22,23)

HIDE SMILES / InChI
Molecular Formula C20H22N4O5
Molecular Weight 398.4133
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19190233 | https://www.ncbi.nlm.nih.gov/pubmed/3040018

Camostat mesilate (FOY-305) is a synthetic f low-molecular weight protease inhibitor. It is able to inhibit trypsin, prostasin, matriptase and plasma kallikrein. In addition camostat attenuates airway epithelial sodium channel function and enhances mucociliary clearance. Camostat mesilate tablets (FOIPAN®) are approved in Japan and used for the treatment of remission of acute symptoms of chronic pancreatitis and postoperative reflux esophagitis.

CNS Activity

CNS Active
3730
Curator's Comment:: Camostat mesilate (FOY-305) is CNS active in animals. No human data available.

Approval Year

Unknown
109281
Targets

Targets

Primary TargetPharmacologyConditionPotency
Trypsin
7
Target ID: CHEMBL2095204
Inhibitor
7728
 1.0 nM [Ki]
Inhibitor
7728
 4.0 nM [Ki]
Inhibitor
7728
 0.576 µM [Ki]
Inhibitor
7728
 50.0 nM [IC50]
Inhibitor
7728
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Approved
8043
FOIPAN

Approved Use

INDICATIONS 1. Remission of acute symptoms of chronic pancreatitis 2. Postoperative reflux esophagitis

Launch Date

7.729344E11
Primary
Approved
8043
FOIPAN

Approved Use

INDICATIONS 1. Remission of acute symptoms of chronic pancreatitis 2. Postoperative reflux esophagitis

Launch Date

7.729344E11
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
New orally active serine protease inhibitors.
1995 Jul 7
Acceleration of ulcer healing by cholecystokinin (CCK): role of CCK-A receptors, somatostatin, nitric oxide and sensory nerves.
1999 Jun 30
Preparation and characterization of biodegradable or enteric-coated microspheres containing the protease inhibitor camostat.
2001 Feb
Different effects of oral administration of synthetic trypsin inhibitor on the pancreas between cholecystokinin-A receptor gene knockout mice and wild type mice.
2002 Jul
Estimation of bioavailability of salmon calcitonin from the hypocalcemic effect in rats (II): effect of protease inhibitor on the pharmacokinetic-pharmacodynamic relationship after intranasal administration.
2003
CCK-58 is the only detectable endocrine form of cholecystokinin in rat.
2003 Aug
Circulating ethanol does not stimulate pancreatic secretion in conscious rats.
2003 Nov
Differential mechanism and site of action of CCK on the pancreatic secretion and growth in rats.
2003 Oct
Calcineurin mediates pancreatic growth in protease inhibitor-treated mice.
2004 May
Preventive and therapeutic effects of the protease inhibitor camostat on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient rats.
2005 Jan
Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats.
2005 Jun
Synthetic protease inhibitor camostat prevents and reverses dyslipidemia, insulin secretory defects, and histological abnormalities of the pancreas in genetically obese and diabetic rats.
2005 May
Calcineurin-dependent and calcineurin-independent signal transduction pathways activated as part of pancreatic growth.
2006 Apr
[Effects of Chinese herbal medicines on spontaneous chronic pancreatitis in rats and the pathological relationships between formulas and syndromes].
2006 Jul
Activation of the mTOR signalling pathway is required for pancreatic growth in protease-inhibitor-fed mice.
2006 Jun 15
Effects of the cholecystokinin A receptor antagonist loxiglumide on the proliferation and cell cycle time of pancreatic acinar cells in rats.
2006 Mar
Strategies of development of antiviral agents directed against influenza virus replication.
2007
Pancreatic diabetes in a follow-up survey of chronic pancreatitis in Japan.
2007 Apr
[Fibrosis markers in heavy alcohol drinkers].
2007 Aug
Induction of early response genes in trypsin inhibitor-induced pancreatic growth.
2007 Feb
Endogenous cholecystokinin reduces food intake and increases Fos-like immunoreactivity in the dorsal vagal complex but not in the myenteric plexus by CCK1 receptor in the adult rat.
2007 Mar
Matrix metalloproteinase gene delivery for liver fibrosis.
2008 Feb
CCK-induced pancreatic growth is not limited by mitogenic capacity in mice.
2008 May
Activation of submucosal but not myenteric plexus of the gastrointestinal tract accompanies reduction of food intake by camostat.
2008 Oct 9
Active site conformational changes of prostasin provide a new mechanism of protease regulation by divalent cations.
2009 May
Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease.
2009 May
ONO 3403, a synthetic serine protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-{alpha} and nitric oxide production and protects mice from lethal endotoxic shock.
2011 Feb
Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.
2013 Jul
Patents

Patents

JP2002114755A
2
JP2006213728A
2
WO2008142397A1
2

Sample Use Guides

In Vivo Use Guide
1. Remission of acute symptoms of chronic pancreatitis. The usual dosage for oral use is 600 mg of camostat mesilate daily in three divided doses. The dosage may be adjusted according to the patient’s symptoms. 2. Postoperative reflux esophagitis. The usual dosage for oral use is 300 mg of camostat mesilate daily in three divided doses after each meal.
Route of Administration: Oral
In Vitro Use Guide
Camostat mesilate (500 uM) inhibited generation of TGF-beta by suppressing plasmin activity and reduced the activity of TGF-beta, which blocked in vitro activation of the rat hepatic stellate cells.
Substance Class Chemical
Created
by admin
on Sat Jun 26 00:22:26 UTC 2021
Edited
by admin
on Sat Jun 26 00:22:26 UTC 2021
Record UNII
0FD207WKDU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CAMOSTAT
INN   MI   WHO-DD  
INN  
Official Name English
CAMOSTAT [WHO-DD]
Common Name English
CAMOSTAT [INN]
Common Name English
CAMOSTAT [MI]
Common Name English
P-GUANIDINOBENZOIC ACID, ESTER WITH (P-HYDROXYPHENYL)ACETIC ACID, ESTER WITH N,N-DIMETHYLGLYCOLAMIDE
Common Name English
Classification Tree Code System Code
WHO-VATC QB02AB04
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
WHO-ATC B02AB04
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
NCI_THESAURUS C783
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
FDA ORPHAN DRUG 338211
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
Code System Code Type Description
MESH
C034532
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
MERCK INDEX
M3000
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY Merck Index
EPA CompTox
59721-28-7
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
DRUG CENTRAL
471
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
CAS
59721-28-7
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
DRUG BANK
DB13729
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
ChEMBL
CHEMBL590799
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
PUBCHEM
2536
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
NCI_THESAURUS
C73213
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
FDA UNII
0FD207WKDU
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
EVMPD
SUB06066MIG
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
INN
5068
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
WIKIPEDIA
CAMOSTAT
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
IUPHAR
6432
Created by admin on Sat Jun 26 00:22:26 UTC 2021 , Edited by admin on Sat Jun 26 00:22:26 UTC 2021
PRIMARY
Related Record Type Details
SARS-COV-2
TARGET ORGANISM->INHIBITOR
nother in vitro study showed that Camostat reduces significantly the infection of Calu-3 lung cells by SARS-CoV-2, the virus responsible for COVID-19.[9]
Structure of CAMOSTAT MESYLATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of CAMOSTAT
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966